NYSE$DNA
Ginkgo Bioworks Holdings · Q4 2023 earnings
Q4 2023 earnings · · Investor relations
Briefing
Announced results for the fourth quarter and year ended December 31, 2023, with a decrease in total revenue primarily due to the expected ramp down of K-12 testing in the Biosecurity segment and the impact of Cell Engineering downstream value share.
Ginkgo Bioworks reported Q4 2023 total revenue of $35 million, a decrease of 65% compared to the prior year, driven by reduced Biosecurity revenue and lower Cell Engineering downstream value share. The company's loss from operations was $(178) million. Year-end cash balance was nearly $950 million.
- Total revenue for Q4 2023 was $35 million, down from $98 million in the comparable prior year period.
- Cell Engineering services revenue for Q4 2023 was $27 million, a 26% decrease from $36 million in the comparable prior year period.
- Biosecurity revenue for Q4 2023 was $8 million with a gross profit margin of 15%.
- Loss from operations for Q4 2023 was $(178) million, compared to $(231) million in the comparable prior year period.
Headline financials
Revenue & EPS history
Ginkgo Bioworks · Revenue · Quarterly
$34.8M
Forward guidance
Ginkgo provided full year 2024 guidance, expecting to add 100-120 new Cell Programs and total revenue of $215-$235 million, including Cell Engineering services revenue of $165-185 million and Biosecurity revenue of at least $50 million.
Tailwinds
- Expects to add 100-120 new Cell Programs to the Cell Engineering platform in 2024.
- Expects Cell Engineering services revenue of $165-185 million in 2024.
- Driven by expected growth in biopharma and government programs.
- Guidance excludes the impact of any potential downstream value share revenue.
- Expects Biosecurity revenue in 2024 of at least $50 million, representing approximate current contracted backlog, with potential upside from additional opportunities in the pipeline.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2023
-2.5%
Avg return
Earnings day
-8.6%
Avg return
5 days after
-12.3%
Avg return
30 days after
32%
7 / 22 earnings
Positive
+25.4%
Q4 2021
Best reaction
-20.8%
Q3 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +1.9% | -17.5% | -19.4% | |
| Q4 2025 | +3.1% | -28.6% | -36.8% | |
| Q3 2025 | -20.8% | -26.0% | -18.1% | |
| Q1 2025 | +14.8% | +28.8% | +17.7% | |
| Q4 2024 | -11.5% | -22.2% | -40.5% | |
| Q3 2024 | -1.8% | -27.3% | +17.9% | |
| Q2 2024 | -1.5% | +2.6% | -48.4% | |
| Q1 2024 | -14.8% | -3.4% | -42.4% | |
| Q4 2023 | -15.1% | -24.3% | -23.7% | |
| Q3 2023 | -18.2% | -16.9% | -11.7% | |
| Q2 2023 | -15.9% | -13.9% | +0.0% | |
| Q1 2023 | -2.9% | -3.6% | +35.0% | |
| Q4 2022 | -4.8% | -7.5% | -9.5% | |
| Q3 2022 | -6.3% | -23.2% | -41.1% | |
| Q2 2022 | +3.0% | -21.5% | -15.4% | |
| Q1 2022 | +3.0% | -1.9% | -2.6% | |
| Q4 2021 | +25.4% | +14.8% | -6.3% | |
| Q4 2019 | -0.3% | -0.5% | -11.8% | |
| Q3 2021 | +8.5% | +4.3% | -15.9% | |
| Q2 2021 | -0.1% | -0.3% | +1.5% | |
| Q1 2021 | +0.0% | -0.2% | +0.2% | |
| Q4 2020 | +0.0% | -0.2% | +0.2% | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro